CompanyGraph
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
603707 · SSE · China
nkf-pharma.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.05B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.08: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.25%Above 5Y avg (0.81%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
27.8%Sustainable
Payback Period
79.6 yr
Last Ex-Dividend
Jun 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.78BCNY2.05B · vs all stocks (USD)
Trailing P/E
22.11xRevenue (TTM)
4.03BCNY599.91M · vs all stocks (USD)
Profit Margin
14.52%Beta
0.3620xvs all stocks
52-Week Change
-31.01%vs all stocks
Market Capitalization
13.78BCNY2.05B · vs all stocks (USD)
Enterprise Value
12.14BCNY1.80B · vs all stocks (USD)
Trailing P/E
22.11xForward P/E
16.58xPrice to Sales (TTM)
3.19xPrice to Book (MRQ)
1.84xEnterprise to Revenue
3.01xEnterprise to EBITDA
12.53xGross Margin
32.31%Profit Margin
14.52%Operating Margin
10.45%Return on Assets (TTM)
4.55%Return on Equity (TTM)
8.64%Revenue (TTM)
4.03BCNY599.91M · vs all stocks (USD)
Revenue per Share (TTM)
2.58CNYUpdated Aug 21, 2026Quarterly Revenue Growth
4.90%Gross Profit (TTM)
1.75BCNY259.96M · vs all stocks (USD)
EBITDA (TTM)
482.26MCNY71.72M · vs all stocks (USD)
Net Income (TTM)
585.83MCNY87.12M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
5.10%Operating Cash Flow (TTM)
1.53BCNY227.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
752.93MCNY111.97M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.25%vs all stocks
5-Year Average Dividend Yield
0.81%vs all stocks
Payout Ratio
27.78%Minority Interest (Equity)
-3.54MCNYFY2025 · Dec 31, 2025Revenue
3.99BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
2.42BCNYFY2025 · Dec 31, 2025Gross Profit
1.57BCNYFY2025 · Dec 31, 2025Operating Income
581.37MCNY86.46M · vs all stocks (USD)
Pre-tax Income
699.42MCNYFY2025 · Dec 31, 2025Income Tax Expense
117.91MCNYFY2025 · Dec 31, 2025Net Income
581.51MCNYFY2025 · Dec 31, 2025EBIT
754.67MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
782.15MCNYFY2025 · Dec 31, 2025Research & Development
348.13MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
475.35MCNYFY2025 · Dec 31, 2025Other Operating Expenses
27.98MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
18.65MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
55.25MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.62BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.62BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
581.51MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
25.33KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.02BCNYFY2025 · Dec 31, 2025Free Cash Flow
464.10MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.10BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
581.51MCNYFY2025 · Dec 31, 2025Other Non-cash Items
93.48MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-321.33MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
670.56MCNYFY2025 · Dec 31, 2025Capital Expenditures
-560.11MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.21BCNYFY2025 · Dec 31, 2025Sale of Investments
3.01BCNYFY2025 · Dec 31, 2025Other Investing Activity
0.00CNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-758.41MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.18BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.99BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-218.42MCNYFY2025 · Dec 31, 2025Other Financing Charges
-29.11MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-54.69MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.62BSharesUpdated Aug 21, 2026Float Shares
433.03MSharesUpdated Aug 21, 2026% Held by Insiders
73.40%vs all stocks
% Held by Institutions
2.47%vs all stocks
Total Cash (MRQ)
3.39BCNY503.71M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.10CNYUpdated Aug 21, 2026Total Debt (MRQ)
2.68BCNY398.27M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3832xCurrent Ratio (MRQ)
2.27xBook Value per Share (MRQ)
4.33CNYUpdated Aug 21, 2026Total Assets
10.34BCNY1.54B · vs all stocks (USD)
Total Current Assets
7.52BCNYFY2025 · Dec 31, 2025Total Liabilities
3.44BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.82BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
238.23MCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.20BCNYFY2025 · Dec 31, 2025Cash
1.10BCNYFY2025 · Dec 31, 2025Cash Equivalents
298.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.39BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.32BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.22BCNYFY2025 · Dec 31, 2025Inventory
3.26BCNYFY2025 · Dec 31, 2025Accounts Payable
589.12MCNYFY2025 · Dec 31, 2025Short-term Debt
2.27BCNYFY2025 · Dec 31, 2025Other Current Liabilities
4.55MCNYFY2025 · Dec 31, 2025Long-term Debt
77.32MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.62BCNYFY2025 · Dec 31, 2025Retained Earnings
4.04BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.90BCNY1.03B · vs all stocks (USD)
Treasury Stock
15.01MCNYFY2025 · Dec 31, 202552-Week Low
6.72CNYUpdated Aug 21, 202652-Week High
11.92CNYUpdated Aug 21, 202652-Week Change
-31.01%vs all stocks
Beta
0.3620xvs all stocks
50-Day MA
7.69CNYUpdated Aug 21, 2026200-Day MA
9.02CNYUpdated Aug 21, 2026Avg 10-Day Volume
11.17MSharesUpdated Aug 21, 2026Avg 30-Day Volume
13.09MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.3600CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.08: safe zoneNotable
Altman Z-Score: 4.08
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.05B, above the global median of $1.15BNotable
Market cap (USD): 2,049,447,340.872Global Median: 1,146,734,693.424
Revenue is $599.91M, above the global median of $520.53MNotable
Revenue (USD): 599,914,470.589Global Median: 520,528,949.311
Levered free cash flow is $111.97M, above the global median of $16.24MNotable
Levered free cash flow (USD): 111,967,504.113Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Mechanical and Electrical Industry Co., Ltd.
1 interpretationCash Backing With OCF Coverage And Cash Near Total Debt
Micron Technology, Inc.
1 interpretationCash Backing With OCF Coverage And Cash Near Total Debt
Root, Inc. Class A Common Stock
1 interpretationCash Backing With OCF Coverage And Cash Near Total Debt